Page 2 - Patrick Ritschel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures and founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, and existing investors Osage University Partners, University of Florida, and Manning Family Foundation. In conjunction with the funding, Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, Ge...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical ... Atsena TherapeuticsDecember 16, 2020 GMT Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors Company expands board of directors and plans to build out team DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medic...

Published: Dec 16, 2020 DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, along with existing investors Osage University Partners, University ...

DURHAM –Atsena Therapeutics, a gene therapy startup backed by Durham-based Hatteras Ventures, has $55 million in new funding and is planning to expand its Triangle workforce. The Durham firm, which also has an office in Durham, disclosed the funding Wednesday morning. Leading the new round are Sofinnova Investments, Abingworth and Lightstone Ventures plus its previous backers. The company will use the funds to advance a clinical trial of a treatment targeting a genetic eye disease (Leber congenital amaurosis or LCA1), which it licensed from drug giant Sanofi, and two other pre-clinical prog...